Skip to main content

Table 1 Baseline characteristics of complete and incomplete response group in patients with nasopharyngeal cancer

From: The goal of primary therapy in non-metastatic nasopharyngeal cancer should be radiological complete response

n Study group  
Incomplete response group (%) Complete response group (%) p
Age (mean ± St.D.) 45.9 ± 14.5 48.3 ± 11.9 0.38
Gender (n) Female 31 (33.7) 36 (39.2) 0.52
Male 7 (7.6) 18 (19.5)
T stage (n) T1 16 (17.4) 20 (21.7) 0.33
T2 8 (8.7) 24 (26.1)
T3/T4 14 (15.2) 10 (10.9)
N stage (n) N0 5 (5.4) 7 (7.6) 0.91
N1 10 (10.9) 12 (13)
N2 20 (21.7) 32 (34.8)
N3 3 (3.3) 3 (3.3)
Clinical stage (n) Stage 1 3 (3.3) 2 (2.2) 0.74
Stage 2 6 (6.5) 11 (12)
Stage 3 25 (27.2) 37 (40.2)
Stage 4a 4 (4.3) 4 (4.3)
Histological type (n) Keratinizing SCC 13 (14.1) 8 (8.7) 0.06
Non- Keratinizing differentiated carcinoma 13 (14.1) 19 (20.7)
Non- Keratinizing differentiated carcinoma 12 (13) 27 (29.3)
Smoking (n) No 22 (23.9) 30 (32.6) 0.82
Yes 16 (17.4) 24 (26.1)
ECOG-PS (n) 0 2 (2.2) 5 (5.4) 0.47
1 36 (39.1) 49 (53.3)
Induction chemotherapy (n) No 22 (23.9) 38 (41.3) 0.21
Yes 16 (17.4) 16 (17.4)
Definitive RT/CRT (n) RT 2 (2.2) 2 (2.2) 0.71
CRT 36 (39.1) 52 (56.5)
Adjuvant chemotherapy (n) No 26 (28.3) 34 (37) 0.58
Yes 12 (13) 20 (21.7)
Cisplatin dose with RT (n) 40 mg/m2 weekly 21 (24.7) 25 (29.4) 0.16
100 mg/m2 once every 3 weeks 12 (14.1) 27 (31.8)
Recurrence/metastasis (n) Yes 15 (16.3) 9 (9.8) 0.014
No 23 (25) 45 (48.9)
  1. SCC squamous cell carcinoma, RT radiotherapy, CRT concurrently radiotherapy